PRA has opened a second office in China as part of its continued expansion in China and the Asia Pacific region. PRA's new facility, located in the central business district of Beijing, will expand the local project teams' ability to meet growing demand for clinical drug development programs.
"As the demand for clinical sites in Asia increase, we continually strive to strengthen our existing operations in China and the Asia Pacific region," said Helen Neal, regional director of clinical operations, Asia Pacific, Middle East, and North Africa. "By adding more professional staff and locations, we can give our clients greater access to these critical markets and geography. In addition to our expansion in China, we continue to increase our presence into new and emerging Southeast Asian regions for access to patients and Resources ."
"We are very excited about our continued expansion into China," said Kent Thoelke, executive vice president, Scientific & Medical Affairs. "In order for global drug development to continue successfully, the need to access patients at high-quality ICH/GCP sites in emerging regions like China is critical. PRA's expansion in this market gives us the ability to bring exciting new clinical trials to a much broader market in China, while providing even greater patient access to our clients and sponsor companies."